CYP2C19 and CYP2D6 are two important pharmacogenes responsible for metabolising a wide range of medications. Both genes exhibit a high level of variation, which can lead to variable activity of the enzymes they encode, with risks of adverse drug reactions and treatment failure. Understanding this variation is therefore of great importance, but the full extent of variability in these genes is not yet documented, particularly for understudied populations. We employed nanopore amplicon DNA sequencing to detect all genetic variants within CYP2C19 and CYP2D6 for a group of Māori individuals, largely affiliated with the Ngāti Porou iwi from Te Tairāwhiti (Gisborne) in Aotearoa New Zealand. From this information, we were able to infer metaboliser phenotypes for the majority of participants and highlight areas for future research, such as understanding the function of the common CYP2D6*71 allele. This knowledge will help ensure equitable application of pharmacogenetic testing within the population of Aotearoa New Zealand.